Day: September 22, 2025

EIB €250 million to support R&D and industrial investments by Nexans _PRESS RELEASE_The operation is partly backed by an InvestEU guarantee.  The loan will enable Nexans to speed up investments in its research and development programme, as well as in its cable production and copper recycling capacities, optimising the use of raw materials and developing the circular economy. This financing is also part of the EIB’s support for REPowerEU, the programme to strengthen the European Union’s energy autonomy.Paris, September 22, 2025 – The European Investment Bank (EIB) has provided €250 million in financing to Nexans, a global leader in cable system design, manufacturing and associated services. The loan will back Nexans’ research, development and innovation programmes for 2024-2029, together with some industrial investments. These...

LEADING EDGE MATERIALS PROVIDES AN UPDATE ON THE NORR KÄRR HREE PROJECT Vancouver, September 21, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) has through its 100% owned Swedish subsidiary Greenna Mineral AB (“GMAB”) submitted supplementary information in respect of the Company’s application for an Exploitation Concession – 25-year mining lease – for the Norra Kärr Heavy Rare Earth Elements Project (“HREE”). The supplements have been prepared in response to requests by the County Administrative Boards of Jönköping and Östergötland and statements from various regional stakeholders for additional information on the possible environmental impacts of the project. The Company’s response has now been sent to the Mining Inspectorate (Sw. Bergsstaten) for...

Hamilton, Bermuda, September 22, 2025 — Golar LNG Limited (the “Company”) (Nasdaq: GLNG), has mandated a syndicate of banks to arrange a series of fixed income investor meetings commencing Monday, September 22. An offering of USD 144A/Reg S denominated benchmark 5NC2 senior unsecured notes (the “Notes”) may follow, subject to market conditions. Important Information This communication is intended for the sole use of the person to whom it is provided by the sender. This announcement and the offer or sale of the Notes may be restricted by law in certain jurisdictions and therefore persons into whose possession this announcement comes should inform themselves about and observe any such restrictions.  This notice does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase, the Notes in...

On Friday, September 19, 2025, the public offering of Arco Vara AS bonds ended. The offering was carried out on the basis of the prospectus approved by the Estonian Financial Supervision Authority on September 8, 2025. As part of the offering, Arco Vara AS offered, as a base volume, 100,000 bonds “EUR 8.80 ARCO VARA BOND 25-2028” with a nominal value of EUR 100 per bond, maturing on 24 September 2028 and bearing a fixed annual interest rate of 8.8% payable quarterly. In the event of oversubscription, Arco Vara AS had the right to increase the offering volume up to 150,000 bonds. In total, 3,392 unique investors participated in the subscription, subscribing for bonds in the amount of EUR 21.9 million. Thus, the base volume of the issue of EUR 10 million was oversubscribed 2.2 times. In accordance with the prospectus, Arco Vara AS exercised...

AB “Ignitis grupė” (hereinafter – the Group) informs that Stelpe solar farm II, controlled by its subsidiary UAB “Ignitis renewables” (hereinafter – Ignitis Renewables), has reached the commercial operation date (hereinafter – COD). The project is in the southern part of Latvia, Bauska municipality. The solar farm, which covers 85 hectares, is equipped with 121 thousand solar panels and has a total installed capacity of 72.5 MW. The total investments in the solar farm, including acquisition and construction costs, will amount to around EUR 54 million. Stelpe solar farm II is a part of the Stelpe solar project, which consists of two sites, each with a capacity of 72.5 MW. The project has a combined installed capacity of 145 MW and will cover the electricity demand of around 70 thousand households. The Group reminds that Stelpe solar farm...

Havila Kystruten expects an EBITDA result of approximately NOK 225 million for the third quarter of 2025. The estimate includes a partial compensation adjustment of contract revenues of NOK 76 million, based on a completed review of the calculation basis for the coastal route contract with The Ministry of Transport. Payment is expected in the fourth quarter of 2025. The coastal route contract is adjusted annually according to an index from Statistics Norway (SSB), adapted for LNG operations since 2022. In collaboration with the Ministry of Transport and SSB, a review of historical compensation adjustments has been carried out. The preliminary result of the review is included in the Q3 estimate. A process is ongoing with SSB regarding two methodological clarifications that could have a further positive effect. These are expected to be resolved...

Press release CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam) DIJON, France – September 22, 2025 (7.30 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the global specialty pharma company developing needle-free auto-injectors for emergency situations, today confirms an additional $11.3 million in funding awarded by the U.S. Biomedical Advanced Research and Development Authority (BARDA). This brings total contract funding for advancing the development of ZEPIZURE® (ZENEO® Midazolam) to $43.3 million. The new funds support regulatory and manufacturing activities that have advanced in refinement and accuracy during the developmental path toward the FDA Emergency Use Authorization (EUA) and NDA (New Drug Application) authorizations. CROSSJECT and...

Sampo plc, stock exchange release, 22 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 19 September 2025                                                  On 19 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  7,751 9.65 AQEU    142,071 9.65 CEUX  41,425 9.65 TQEX  204,753 9.65 XHELTOTAL 396,000 9.65  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionRecommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the EUParis and Tarrytown, September 22, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the EU for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. This recommendation covers those aged 12 years and above with moderate to severe disease, with inadequate response to histamine-1 antihistamines (H1AH), and who are naive to...

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the European Union (EU) TARRYTOWN, N.Y. and PARIS, Sept. 22, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Dupixent® (dupilumab) in the European Union (EU) for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents. This recommendation covers those aged 12 years and above with moderate-to-severe disease, with inadequate response to histamine-1 antihistamines (H1AH)...